Log In
Print
BCIQ
Print
Print this Print this
 

Cytomegalovirus (CMV) vaccine, TransVax (ASP0113, VCL-CB01)

  Manage Alerts
Collapse Summary General Information
Company Vical Inc.
DescriptionDNA vaccine encoding phosphoprotein 65 and glycoprotein B formulated with poloxamer
Molecular Target Human cytomegalovirus (CMV) phosphoprotein 65 ; Human cytomegalovirus (CMV) glycoprotein B
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationCytomegalovirus (CMV)
Indication DetailsPrevent cytomegalovirus (CMV) reactivation in CMV-seropositive hematopoietic stem cell transplant recipients; Prevent cytomegalovirus (CMV) reactivation in immunosuppressed CMV-seropositive hematopoietic stem cell transplant recipients; Prevent cytomegalovirus (CMV) reactivation in solid organ transplant recipients; Prevent cytomegalovirus reactivation in hematopoietic cell transplant recipients
Regulatory Designation

Partner

Astellas Pharma Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today